argenx halts Sjogren's trial as argenx stock falls 15.58 percent

Published on 10/08/2026 at 11:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The UNITY study missed its primary endpoint at Week 48. argenx stock costs EUR 700.40 on October 8, 2026 versus EUR 829.70.

Extremmakro: Iridisierende blaue und violette Flüssigkeitstropfen auf einem Glasobjektträger, kristallscharfe Mitte mit weichem Bokeh, wissenschaftliche Abstraktion — Argenx NL0010832176 Extremmakro zeigt irisierende Flüssigkeitstropfen auf einem wissenschaftlichen Glas-Objektträger unter Laborlicht, Illustration mit AI erstellt.

argenx (ISIN NL0010832176) was trading at EUR 700.40 at Lang & Schwarz on October 8, 2026 at 11:42 a.m. CEST, down 15.58 percent versus the EUR 829.70 prior close. According to StockTitan on October 8, 2026, argenx halted its Phase 3 UNITY study of efgartigimod in moderate-to-severe Sjogren's disease after an interim analysis found that the trial could not meet its primary endpoint. The steep market reaction puts the late-stage pipeline setback ahead of a separate positive clinical update released the same day.

UNITY setback hits late-stage plans

The UNITY study was designed to compare weekly efgartigimod with placebo in patients with primary Sjogren's disease. Its primary measure was the change in systemic disease activity at Week 48, making the result important for argenx's effort to expand efgartigimod beyond its established autoimmune indications.

The trial stop removes one development path from the company's near-term expansion plan. StockTitan reported that the decision followed a recommendation from an Independent Data Monitoring Committee, while safety remained consistent with the established profile of efgartigimod.

FB102 supplies a quantified counterpoint

argenx also reported positive topline results for FB102 in a Phase 2 celiac disease study. GlobeNewswire reported on October 8, 2026, that the study met its primary endpoint, with a p-value of 0.0176 versus placebo. The trial enrolled 126 patients and measured the change in the villus height-to-crypt depth ratio after a gluten challenge.

That result gives argenx an earlier-stage pipeline asset to advance toward Phase 3, but it does not erase the immediate clinical disappointment in UNITY. The contrast matters because one program added evidence in celiac disease while another failed to support a late-stage expansion opportunity.

Stock reaction resets the reference point

The Lang & Schwarz quote shows EUR 700.40 at 11:42 a.m. CEST on October 8, 2026, compared with EUR 829.70 at the prior close. The 15.58 percent decline is the market's clearest same-day measure of how investors have weighed the UNITY result against the FB102 update.

argenx remains an immunology biotechnology company with commercial exposure to VYVGART and a broader antibody pipeline. The next valuation debate centers on whether growth from established products and newer programs can offset the loss of a Sjogren's expansion opportunity.

The further course of trading is shown by the continuously updated real-time quote of argenx stock.